Stallergenes S.A. - Product Pipeline Review - 2014 - Hawaii News Now - KGMB and KHNL

Stallergenes S.A. - Product Pipeline Review - 2014

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE ReportBuyer



 

 

 

LONDON, June 17, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Stallergenes S.A. - Product Pipeline Review - 2014



http://www.reportbuyer.com/pharma_healthcare/treatments/stallergenes_s_a_product_pipeline_review_2013.html

Stallergenes S.A. - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Stallergenes S.A. - Product Pipeline Review - 2014', provides an overview of the Stallergenes S.A.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Stallergenes S.A.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Scope

- The report provides brief overview of Stallergenes S.A. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Stallergenes S.A.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Stallergenes S.A.'s pipeline products


Reasons to buy

- Evaluate Stallergenes S.A.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Stallergenes S.A. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Stallergenes S.A.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Stallergenes S.A. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Stallergenes S.A.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Stallergenes S.A. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents

Stallergenes S.A. Snapshot 5
Stallergenes S.A. Overview 5
Key Information 5
Key Facts 5
Stallergenes S.A. - Research and Development Overview 6
Key Therapeutic Areas 6
Stallergenes S.A. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
Stallergenes S.A. - Pipeline Products Glance 12
Stallergenes S.A. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
Stallergenes S.A. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Stallergenes S.A. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
Stallergenes S.A. - Drug Profiles 17
S-524101 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
rBet v1 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Ragweed Pollen Allergen Extract 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Japanese Cedar Pollen Tablet 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Recombinant Protein for Birch Pollen Allergy 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Drugs for Allergy 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Stallergenes S.A. - Pipeline Analysis 25
Stallergenes S.A. - Pipeline Products by Route of Administration 25
Stallergenes S.A. - Pipeline Products by Molecule Type 26
Stallergenes S.A. - Recent Pipeline Updates 27
Stallergenes S.A. - Dormant Projects 28
Stallergenes S.A. - Locations And Subsidiaries 29
Head Office 29
Other Locations & Subsidiaries 29
Appendix 31
Methodology 31
Coverage 31
Secondary Research 31
Primary Research 31
Expert Panel Validation 31
Contact Us 32
Disclaimer 32

List of Tables

Stallergenes S.A., Key Information 5
Stallergenes S.A., Key Facts 5
Stallergenes S.A. - Pipeline by Indication, 2014 7
Stallergenes S.A. - Pipeline by Stage of Development, 2014 8
Stallergenes S.A. - Monotherapy Products in Pipeline, 2014 9
Stallergenes S.A. - Partnered Products in Pipeline, 2014 10
Stallergenes S.A. - Partnered Products/ Combination Treatment Modalities, 2014 11
Stallergenes S.A. - Phase III, 2014 12
Stallergenes S.A. - Phase II, 2014 13
Stallergenes S.A. - Phase I, 2014 14
Stallergenes S.A. - Preclinical, 2014 15
Stallergenes S.A. - Discovery, 2014 16
Stallergenes S.A. - Pipeline by Route of Administration, 2014 25
Stallergenes S.A. - Pipeline by Molecule Type, 2014 26
Stallergenes S.A. - Recent Pipeline Updates, 2014 27
Stallergenes S.A. - Dormant Developmental Projects,2014 28
Stallergenes S.A., Subsidiaries 29

List of Figures

Stallergenes S.A. - Pipeline by Top 10 Indication, 2014 7
Stallergenes S.A. - Pipeline by Stage of Development, 2014 8
Stallergenes S.A. - Monotherapy Products in Pipeline, 2014 9
Stallergenes S.A. - Pipeline by Top 10 Route of Administration, 2014 25
Stallergenes S.A. - Pipeline by Top 10 Molecule Type, 2014 26


Read the full report:
Stallergenes S.A. - Product Pipeline Review - 2014

http://www.reportbuyer.com/pharma_healthcare/treatments/stallergenes_s_a_product_pipeline_review_2013.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

 

©2012 PR Newswire. All Rights Reserved.